277 related articles for article (PubMed ID: 31331960)
41. Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.
Thomas RJ; Webber D; Collinge A; Stagg AJ; Bailey SC; Nunez A; Gates A; Jayasekera PN; Taylor RR; Eley S; Titball RW
Infect Immun; 2009 Apr; 77(4):1315-23. PubMed ID: 19188359
[TBL] [Abstract][Full Text] [Related]
42. A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.
Zhang Y; Mena P; Romanov G; Lin JS; Smiley ST; Bliska JB
Infect Immun; 2012 Jan; 80(1):206-14. PubMed ID: 22064714
[TBL] [Abstract][Full Text] [Related]
43. Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis.
Wang X; Singh AK; Zhang X; Sun W
Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32152195
[TBL] [Abstract][Full Text] [Related]
44. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection.
Lin JS; Kummer LW; Szaba FM; Smiley ST
J Immunol; 2011 Feb; 186(3):1675-84. PubMed ID: 21172869
[TBL] [Abstract][Full Text] [Related]
45. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague.
Garmory HS; Griffin KF; Brown KA; Titball RW
Vaccine; 2003 Jun; 21(21-22):3051-7. PubMed ID: 12798649
[TBL] [Abstract][Full Text] [Related]
46. Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model.
Ali R; Naqvi RA; Kumar S; Bhat AA; Rao DN
Scand J Immunol; 2013 May; 77(5):361-71. PubMed ID: 23480362
[TBL] [Abstract][Full Text] [Related]
47. Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor.
Do Y; Didierlaurent AM; Ryu S; Koh H; Park CG; Park S; Perlin DS; Powell BS; Steinman RM
Vaccine; 2012 Oct; 30(45):6359-67. PubMed ID: 22947140
[TBL] [Abstract][Full Text] [Related]
48. Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain.
Mellado-Sanchez G; Ramirez K; Drachenberg CB; Diaz-McNair J; Rodriguez AL; Galen JE; Nataro JP; Pasetti MF
Comp Immunol Microbiol Infect Dis; 2013 Mar; 36(2):113-28. PubMed ID: 23195858
[TBL] [Abstract][Full Text] [Related]
49. Yersinia pestis caf1 variants and the limits of plague vaccine protection.
Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O
Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051
[TBL] [Abstract][Full Text] [Related]
50. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.
Sun W; Roland KL; Kuang X; Branger CG; Curtiss R
Infect Immun; 2010 Mar; 78(3):1304-13. PubMed ID: 20086087
[TBL] [Abstract][Full Text] [Related]
51. Protecting against plague: towards a next-generation vaccine.
Williamson ED; Oyston PC
Clin Exp Immunol; 2013 Apr; 172(1):1-8. PubMed ID: 23480179
[TBL] [Abstract][Full Text] [Related]
52. Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.
Branger CG; Torres-Escobar A; Sun W; Perry R; Fetherston J; Roland KL; Curtiss R
Vaccine; 2009 Aug; 27(39):5363-70. PubMed ID: 19596407
[TBL] [Abstract][Full Text] [Related]
53. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
54. Different strategies for preparation of non-tagged rV270 protein and its efficacy against Yersinia pestis challenge.
Wang W; Qi ZZ; Zhang QW; Wu BC; Zhu ZW; Yang YH; Cui BZ; Dai RX; Qiu YF; Wang ZY; Guo ZB; Shi TX; Wang H; Yang RF; Wang XY
Biomed Environ Sci; 2010 Oct; 23(5):333-40. PubMed ID: 21112480
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
[TBL] [Abstract][Full Text] [Related]
56. Polymorphism in the
Daniel C; Dewitte A; Poiret S; Marceau M; Simonet M; Marceau L; Descombes G; Boutillier D; Bennaceur N; Bontemps-Gallo S; Lemaître N; Sebbane F
Front Immunol; 2019; 10():1830. PubMed ID: 31428104
[TBL] [Abstract][Full Text] [Related]
57. HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.
Batra L; Verma SK; Nagar DP; Saxena N; Pathak P; Pant SC; Tuteja U
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3322. PubMed ID: 25474358
[TBL] [Abstract][Full Text] [Related]
58. Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.
Li B; Du C; Zhou L; Bi Y; Wang X; Wen L; Guo Z; Song Z; Yang R
Clin Vaccine Immunol; 2012 Feb; 19(2):228-34. PubMed ID: 22190397
[TBL] [Abstract][Full Text] [Related]
59. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
60. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
